

AUTHOR INDEX

Albain, K.S., 284
Almstedt, M., 511
Altomonte, M., 473, 503
Arlen, P.M., 549
Ashton, R.W., 253

Baggetto, L.G., 583
Barakat, S., 583
Barosi, G., 395
Benimetskaya, L., 563
Berlin, J.D., 52
Biddle, V.R., 232
Blanke, C.D., 69
Bromer, M.Q., 3
Browner, I., 145

Calabro, L., 503
Carducci, M.A., 145
Cervantes, F., 395
Chagraoui, H., 365
Cheville, A.L., 219
Cho, L.C., 293
Chow, E., 156
Choy, H., 293
Chung, D.C., 11
Cinti, C., 452
Claus, R., 511
Cohen, S.D., 237
Coldwell, D.M., 169
Collins, T.S., 61
Coral, S., 473

Danielli, R., 473
Dayan, G., 583
Deeg, H.J., 414
Degan, M., 503
de Vos, D., 437
Di Giacomo, A.M., 473, 503
DiPaola, R.S., 549
Dumont, J., 279
Dowell, J.E., 293

Feeney, K., 596
Feigenberg, S., 156
Fonsatti, E., 503
Frankel, A.E., 591
Fratta, E., 473
French INSERM Network on Myelofibrosis
With Myeloid Metaplasia, 373

Garwood, D., 293
Gattei, V., 503
Gerson, S., 535
Gill, S., 24
Giordano, A., 452
Goldberg, R.M., 35
Grem, J.L., 120
Gruis, N.A., 479

Haller, D.G., 95
Haluszka, O., 174
Harrington, K.J., 573
Herbst, R.S., 315
Hermiston, T., 537
Hurwitz, H.I., 61

Isobe, T., 315
Issa, J.-P.J., 521

Jett, J.R., 253
Jo, W.-S., 11
Johnson, D.H., 251, 329

Kairys, J., 596
Kash, K.M., 211
Kaufman, H.L., 549
Kim, P.S., 194
Kirn, D., 537
Konski, A., 156
Kunkel, E.J., 211
Kvasnicka, H.M., 380

Labialle, S., 583
Lagman, R., 134
Lamaj, E., 473
Laskin, J.J., 251, 329
Lattime, E.C., 535
Le Bousse-Kerdiles, M.-C., 373
Le Chevalier, T., 279
Levy, M.H., 131, 179, 237
Lockhart, C., 52
Lubbert, M., 511

Macaluso, M., 452
Mago, R., 211
Maio, M., 435, 473, 503
Manti, S., 563
Martyre, M.-C., 373
Massion, P.P., 259
McLeod, H.L., 113
Meropol, N.J., 1
Mesa, R.A., 403
Michaud, M., 583
Migliaccio, A.R., 365
Milch, R.A., 165
Miller, V.A., 299
Milton, D.T., 299
Momparler, R.L., 443
Montanari, M., 452
Monti, D.A., 225
Murgo, A.J., 458
Mutti, L., 336

Nguyen, D.M., 488

Odenike, O., 357, 422
O'Neil, B.H., 35
Onn, A., 315

Paice, J.A., 200
Pandha, H., 573
Paoletti, F., 365
Pass, H.I., 269
Porta, C., 336

Reilly, J.T., 359
Relph, K.L., 573
Ribas, A., 536
Rigal, D., 583
Rosenfeld, C.S., 465
Ruan, D.T., 85

Samuel, T.A., 179
Sanborn, R., 69
Sandler, A.B., 251, 329
Schapira, L., 139
Schrump, D.S., 488
Sewell, P.E., 169
Sigalotti, L., 473, 503
Simicope, F.A., 24
Soria, J.-C., 279
Spangler, A., 293
Stein, C.A., 563
Suh, D.Y., 591
Sun, W., 95

Tan, B.R., 113
Tefferi, A., 403, 422
Tejpar, S., 43
Tensen, C.P., 479
Thiele, J., 380
Thorne, S.H., 537
Torosian, M.H., 232
Toyota, M., 521

van Besien, K., 414
Van Cutsem, E., 43
van der Velden, P.A., 479
van Doorn, R., 479
Vannucchi, A.M., 365
Verslype, C., 43
Vogelzang, N.J., 336
von Mehren, M., 76
Von Roenn, J.H., 200

Walsh, D., 134
Wardwell Jr., N.R., 259
Warren, R.S., 85
Weinberg, D.S., 3
Wendling, F., 365
West, H., 284
Willemze, R., 479
Willett, C.G., 103
Wong, L., 591

Yang, J., 225

Zhu, A.X., 103

AUTHOR INDEX

Albain, K.S., 284
Almstedt, M., 511
Altomonte, M., 473, 503
Arlen, P.M., 549
Ashton, R.W., 253

Baggetto, L.G., 583
Barakat, S., 583
Barosi, G., 395
Benimetskaya, L., 563
Berlin, J.D., 52
Biddle, V.R., 232
Blanke, C.D., 69
Bromer, M.Q., 3
Browner, I., 145

Calabro, L., 503
Carducci, M.A., 145
Cervantes, F., 395
Chagraoui, H., 365
Cheville, A.L., 219
Cho, L.C., 293
Chow, E., 156
Choy, H., 293
Chung, D.C., 11
Cinti, C., 452
Claus, R., 511
Cohen, S.D., 237
Coldwell, D.M., 169
Collins, T.S., 61
Coral, S., 473

Danielli, R., 473
Dayan, G., 583
Deeg, H.J., 414
Degan, M., 503
de Vos, D., 437
Di Giacomo, A.M., 473, 503
DiPaola, R.S., 549
Dumont, J., 279
Dowell, J.E., 293

Feeney, K., 596
Feigenberg, S., 156
Fonsatti, E., 503
Frankel, A.E., 591
Fratta, E., 473
French INSERM Network on Myelofibrosis
With Myeloid Metaplasia, 373

Garwood, D., 293
Gattei, V., 503
Gerson, S., 535
Gill, S., 24
Giordano, A., 452
Goldberg, R.M., 35
Grem, J.L., 120
Gruis, N.A., 479

Haller, D.G., 95
Haluszka, O., 174
Harrington, K.J., 573
Herbst, R.S., 315
Hermiston, T., 537
Hurwitz, H.I., 61

Isobe, T., 315
Issa, J.-P.J., 521

Jett, J.R., 253
Jo, W.-S., 11
Johnson, D.H., 251, 329

Kairys, J., 596
Kash, K.M., 211
Kaufman, H.L., 549
Kim, P.S., 194
Kirn, D., 537
Konski, A., 156
Kunkel, E.J., 211
Kvasnicka, H.M., 380

Labialle, S., 583
Lagman, R., 134
Lamaj, E., 473
Laskin, J.J., 251, 329
Lattime, E.C., 535
Le Bousse-Kerdiles, M.-C., 373
Le Chevalier, T., 279
Levy, M.H., 131, 179, 237
Lockhart, C., 52
Lubbert, M., 511

Macaluso, M., 452
Mago, R., 211
Maio, M., 435, 473, 503
Manti, S., 563
Martyre, M.-C., 373
Massion, P.P., 259
McLeod, H.L., 113
Meropol, N.J., 1
Mesa, R.A., 403
Michaud, M., 583
Migliaccio, A.R., 365
Milch, R.A., 165
Miller, V.A., 299
Milton, D.T., 299
Momparler, R.L., 443
Montanari, M., 452
Monti, D.A., 225
Murgo, A.J., 458
Mutti, L., 336

Nguyen, D.M., 488

Odenike, O., 357, 422
O'Neil, B.H., 35
Onn, A., 315

Paice, J.A., 200
Pandha, H., 573
Paoletti, F., 365
Pass, H.I., 269
Porta, C., 336

Reilly, J.T., 359
Relph, K.L., 573
Ribas, A., 536
Rigal, D., 583
Rosenfeld, C.S., 465
Ruan, D.T., 85

Samuel, T.A., 179
Sanborn, R., 69
Sandler, A.B., 251, 329
Schapira, L., 139
Schrump, D.S., 488
Sewell, P.E., 169
Sigalotti, L., 473, 503
Simicope, F.A., 24
Soria, J.-C., 279
Spangler, A., 293
Stein, C.A., 563
Suh, D.Y., 591
Sun, W., 95

Tan, B.R., 113
Tefferi, A., 403, 422
Tejpar, S., 43
Tensen, C.P., 479
Thiele, J., 380
Thorne, S.H., 537
Torosian, M.H., 232
Toyota, M., 521

van Besien, K., 414
Van Cutsem, E., 43
van der Velden, P.A., 479
van Doorn, R., 479
Vannucchi, A.M., 365
Verslype, C., 43
Vogelzang, N.J., 336
von Mehren, M., 76
Von Roenn, J.H., 200

Walsh, D., 134
Wardwell Jr., N.R., 259
Warren, R.S., 85
Weinberg, D.S., 3
Wendling, F., 365
West, H., 284
Willemze, R., 479
Willett, C.G., 103
Wong, L., 591

Yang, J., 225

Zhu, A.X., 103

SUBJECT INDEX

A beta fiber, 198
A delta fiber, 198
Abdominal radiation, for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia, 408-410
Aberrant crypt foci, 25
as potential surrogate biomarker, 30-31
Aberrant DNA methylation, in cancer, 521
causes of
accelerating factors, 525-526
gene expression factor, 526
seed and spread model, 525
selective advantage, 526-527
in cutaneous malignancies
basal cell carcinoma, 480-481
lymphoma, 483-484
melanoma, 481-483
relationship with exposure to ultraviolet radiation, 484
squamous cell carcinoma, 480-481
Acetaminophen, 183-184
Acupuncture, 226
Acute myelogenous leukemia, clinical development of decitabine for combination therapy, 469
monotherapy, 468-469
Adenocarcinoma, lung, uracil tegafur adjuvant chemotherapy, 281
Adenomatous polyps, colorectal cancer risk and, 4-5
Adenoviral vectors, for cancer gene therapy, 573-575
adverse outcomes, 580
clinical applications, 576
gene replacement therapy, 578-579
immunotherapy and, 576-578
oncolytic virotherapy, 579-580
suicide gene therapy, 578
targeting of
transcriptional, 575-576
transductional, 575
Affinitak, in non-small cell lung cancer, 320
Age, effects on chemotherapy of non-small cell lung cancer, 308-310
Algomed pump, 195
Allogeneic hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 414-419
ALVAC, 80
American Cancer Society, 216
Amsterdam criteria, for hereditary nonpolyposis colon cancer, 16
Analgesic
for cancer pain relief, 181-184
co-analgesic, 188
dosing of, 183-184
opioid, sequential trials of, 188
Androgens, for anemia in myelofibrosis with myeloid metaplasia, 423
Anemia, in myelofibrosis with myeloid metaplasia, androgens for, 423
Angiogenesis, 61-62
in myelofibrosis with myeloid metaplasia, 385-386
pro, factors for, 62
Angiogenesis inhibitors
in clinical development, 66
factors for, 62
in non-small cell lung cancer, 320-323
Angiogenesis inhibitors (*Continued*)
trials of, in colorectal cancer, 63
Angiogenic myeloid metaplasia, *see* Myelofibrosis with myeloid metaplasia
Angiozyme, in colorectal cancer, 65, 66
Anorexia, 202-204
pharmacologic agents for, 201
Antiangiogenic agents, for myelofibrosis with myeloid metaplasia, 424-426
Anticonvulsant, as co-analgesic, 189-190
Anti-EGFR monoclonal antibody therapy
in malignant pleural mesothelioma, 341-343
in non-small cell lung cancer, 317-318
Antigen
processing of, 77
types of, in colorectal cancer, 78
Anti-idiotypic vaccine, trial of, 79
Antineoplastic activity, of decitabine in animal models, 445-446
Antisense oligonucleotides, for oncogene inactivation
Bcl-2 inhibition by, 568-569
cellular internalization, 564-565
chemically synthesized, properties of, 564
clinical utility of phosphodiester oligonucleotides, 563-564
for multidrug resistant cancer, 584-585, 587
phosphorothioate oligonucleotides
efficacy of, and RNase H, 566
general properties, 565
nonspecific effects, 565-566
pharmacokinetics, 566-569
second-generation oligonucleotides, pharmacokinetics, 568
Anti-VEGFR monoclonal antibody therapy, in non-small cell lung cancer, 320
Anxiety, treatment of, 212-214
APC gene, 15
in colorectal screening, 9
Apoptosis
activation by decitabine in epigenetic cancer therapy, 466
and proliferation, in myelofibrosis with myeloid metaplasia, 383-385
Argon plasma coagulation, 175
Aspirin
chemoprevention trial and, 26
colorectal cancer and, 25-28
Astler-Coller classification, modified, in colorectal cancer, 96
Atypical capsular melanocytes, 596-597
Autofluorescence bronchoscopy, in non-small cell lung cancer screening, 254
Autologous hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 419-420
Avastin, in malignant pleural mesothelioma, 343-344
Avipox, 80
5-Aza-2'-deoxycytidine, *see* Decitabine
5-AZA-CdR, *see* Decitabine
Azacitidine, in epigenetic cancer therapy
combinations with histone deacetylase inhibitors, 461
dose-schedule optimization of, 459-460
for myeloid neoplasms, 511-512
restoring or enhancing sensitivity to other therapy, 460-461
5-AZA-CR, *see* Azacitidine
5-Azacytidine, *see* Azacitidine
Azanucleosides, low-dose, in epigenetic therapy of myeloid neoplasms, 511-512
Azoxymethane, 53

Cancer testis antigens
and epigenetic immunotherapy of solid tumors, 474
in hematopoietic malignancies
expression of, 516-517
as potential *in vivo* targets of demethylating agents, 515-516

CAP chemotherapy regimen, in non-small cell lung cancer, 279

Capecitabine, 98
adjuvant, 44-46
in combination therapy, for colorectal cancer, 46-50
irinotecan plus, in colorectal cancer, 48, 49
oral, in colorectal cancer, 43-44
oxaliplatin plus, in colorectal cancer, 46, 47, 49
radiation plus, in rectal cancer, 49-50, 106

Carbamazepine, 187, 189

Carboplatin, docetaxel chemotherapy regimen, in non-small cell lung cancer, 301-302

Carboplatin, etoposide chemotherapy regimen, in non-small cell lung cancer, 289-291

Carboplatin, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 300, 302

Carboplatin, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 281, 287-289, 301-302, 306, 308

Carcinoembryonic antigen (CEA)
and poxviral vaccines
in cancer immunotherapy, 550-552
vaccines and, 76-77

Catheter, in direct drug delivery, 195-196

CD34⁺ progenitor cells, in myelofibrosis with myeloid metaplasia, 386-388

CEA, see Carcinoembryonic antigen

Celecoxib, 183
chemoprevention trial of, 26
in colorectal cancer, 65, 66
in combination therapy, for colorectal cancer, 73

Celiac plexus neurolysis, 176

Cell cycle, progression in cancer
p14^{ARF}/mdm2/p53 pathway, 454-455
pRB/p16^{INK4}/cyclin D1 pathway, 452-454

Celoxib, in non-small cell lung cancer, 323

Central nervous system metastasis, in non-small cell lung cancer, 293-296
prophylactic cranial irradiation, 293-296

Cetuximab, 54-55, 109, 117
for chemotherapy in non-small cell lung cancer, 317-318
clinical development of, 55-56

CHART, see Continuous hyperfractionated accelerated radiation therapy

Chemical neurolysis, 196

Chemoprevention, in lung cancer, 265

Chemoradiation, 103-104
in rectal cancer, 49-59

Chemotherapy
adjuvant
in colorectal cancer, 96-99
hepatic artery infusional, 89-90
in non-small cell lung cancer, 251, 279-283
uracil tegafur, in lung adenocarcinoma, 281

affinitak, in non-small cell lung cancer, 320

bevacizumab, in non-small cell lung cancer, 321

beaxarotene, in non-small cell lung cancer, 320

in bronchioloalveolar carcinoma, 330-331

cetuximab, in non-small cell lung cancer, 317-318

combination, in non-small cell lung cancer, 284-291, 299-312

consolidation, in non-small cell lung cancer
docetaxel, 288-289
paclitaxel, 290

cytotoxic, in non-small cell lung cancer, 299-312

epigenetic, see Chemotherapy, epigenetic

erlotinib, in non-small cell lung cancer, 318-319

gefitinib, in non-small cell lung cancer, 318-319

gemcitabine monotherapy, in non-small cell lung cancer, 309

induction, for non-small cell lung cancer, 284-291

Chemotherapy (Continued)
induction cisplatin, for non-small cell lung cancer, 286-287
irinotecan monotherapy, in non-small cell lung cancer, 301
lonafarnib, in non-small cell lung cancer, 319
in malignant pleural mesothelioma, 336-341
monotherapy v combination, in non-small cell lung cancer, 304-305
neovastat, in non-small lung cancer, 320

nonplatinum-based doublets, in non-small cell lung cancer, 302-304

paclitaxel monotherapy, non-small cell lung cancer, 308-309

palliative, see Palliative chemotherapy

phase I trials of, 152-154

platinum-based doublets, in non-small cell lung cancer, 300-302

plus hyperfractionated accelerated radiation therapy, in non-small cell lung cancer, 287-288

plus hyperfractionated radiation therapy
in non-small cell lung cancer, 287

v thoracic radiotherapy, in non-small cell lung cancer, 287-288, 290-291

plus radiotherapy, in non-small cell lung cancer, 286-291

plus surgery and radiotherapy, in non-small cell lung cancer, 284-285

primostat, in non-small cell lung cancer, 320

in refractory non-small cell lung cancer, 306-307

in relation to age, 308-310

retinoids, in non-small cell lung cancer, 320

semaxanib, in non-small cell lung cancer, 321

tipifarnib, in non-small cell lung cancer, 319

trastuzumab, in non-small cell lung cancer, 319

v continuous hyperfractionated accelerated radiation therapy, in non-small cell lung cancer, 287

vinorelbine monotherapy, in non-small cell lung cancer, 300, 308-309

Chemotherapy, epigenetic
azacitidine in
combinations with histone deacetylase inhibitors, 461
dose-schedule optimization of, 459-460
restoring or enhancing sensitivity to other therapy, 460-461

decitabine in
for acute myelogenous leukemia, 468-469
antineoplastic activity in animal models, 445-446
apoptosis activation by, 466
background of, 437-438
cellular pharmacology of, 444-445
chemotherapy resensitization by, 466-467
for chronic myelogenous leukemia, 469-470
combinations with histone deacetylase inhibitors, 461
dose-schedule optimization of, 447-449, 459-460
drug resistance of, 445
enzyme DNA adduct formation by, 466
genomic hypomethylation by, 466
hematopoietic toxicity of, 446-447
history of, 438-440, 465
induction of tumor-associated antigens by, 466
mechanism of action, 466
metabolism and molecular mechanism of action, 443-444
for myelodysplastic syndrome, 468
optimizing silenced gene reexpression with, 470
pharmacokinetics of, 447
phase I and II studies, 446
present studies of, 440-441
recent phase I clinical trials of, 467
reduced telomerase activity by, 466
restoring or enhancing sensitivity to other therapy, 460-461
for solid tumors, 470
for lung cancer, 488-499
chromatin remodeling agents, 493-498
for myeloid neoplasms
cancer testis antigens and, 515-517
low-dose azanucleosides, 511-512
in vivo markers of demethylation, 512-515

Chemotherapy resensitization, by decitabine in epigenetic cancer therapy, 466-467

Chest roentgenogram, in non-small cell lung cancer screening, 254-257

CHOICES, 147, 148

Choline Mg trisalicylate, 187

Chromatin remodeling agents, for epigenetic lung cancer therapy, 488-499
 clinical trials of, 497-498
 for lung cancer prevention, 498
 preclinical studies of, 493-497

Chromoendoscopy, 25

Chromosomal abnormalities, in myeloid metaplasia with myelofibrosis
 chromosome 1, 360
 chromosome 8, 360
 chromosome 9, 360
 chromosome 13, 360-361
 chromosome 20, 361

Chromosomal instability, 124

Chromosome 18q, 125

Chronic idiopathic myelofibrosis, *see* Myelofibrosis with myeloid metaplasia

Chronic myelogenous leukemia, clinical development program of decitabine for, 469-470

CI-1033, clinical development of, 55, 57

Cisplatin, docetaxel chemotherapy regimen, in non-small cell lung cancer, 301-302

Cisplatin, doxorubicin, cyclophosphamide chemotherapy regimen, in non-small cell lung cancer, 279

Cisplatin, etoposide chemotherapy regimen, in non-small cell lung cancer, 309
 adjuvant chemotherapy, 280-281
 induction chemotherapy, 285-286, 288-289

Cisplatin, gemcitabine, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-305

Cisplatin, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 300-302
 induction chemotherapy, 288

Cisplatin, ifosfamide, mitomycin chemotherapy regimen, in non-small cell lung cancer, 284

Cisplatin, induction chemotherapy, in non-small cell lung cancer, 286-287

Cisplatin, irinotecan chemotherapy regimen, in non-small cell lung cancer, 301

Cisplatin, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 302, 309
 induction chemotherapy, 288

Cisplatin, pemetrexed chemotherapy regimen, in malignant pleural mesothelioma, 340-341

Cisplatin, vinblastine, mitomycin chemotherapy regimen, in non-small cell lung cancer, 306
 induction chemotherapy, 287

Cisplatin, vinblastine chemotherapy regimen, in non-small cell lung cancer, 286-287

Cisplatin, vindesine, mitomycin chemotherapy regimen, in non-small cell lung cancer, 280-281

Cisplatin, vindesine chemotherapy regimen, in non-small cell lung cancer, 284-285, 300-301, 308

Cisplatin, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 301-302, 308
 adjuvant chemotherapy, 281
 induction chemotherapy, 288

Clinical features, of bronchioalveolar carcinoma, 329

Clonazepam, 187, 189

Codeine, 182, 183-184

Colon-breast cancer syndrome, 19

Colonic obstruction, palliation of, 175

Colonoscopy
 for colorectal cancer, 5-6
 virtual, 8

Colorectal cancer
 alarm symptoms for, 4
 average-risk patients for, 5, 6
 chemoprevention trials in, 26
 colonoscopy for, 5-6
 first-line therapy in, 35-37
 genetic model in, 11-13

Colorectal cancer (Continued)
 hepatic metastases of, hepatic resection for, 85-86
 high-risk patients for, 4
 incidence of, 1, 3, 24
 inherited syndromes with risk of, 12
 intermediate-risk patients for, 4-5
 Knudson hypothesis of, 13
 overview of, 1
 recognizing hereditary syndromes of, 13
 risk stratification for, 3-4
 screening recommendations for, 5
 second-line chemotherapy in, 40
 stage II, adjuvant therapy for, 99-100
 staging of, 95-96
 two hit hypothesis of, 13

Combination chemotherapy, v monotherapy, in non-small cell lung cancer, 304-305

Combined modality therapy
 in non-small cell lung cancer, 279-291, 293-296
 chemotherapy plus fractionated radiation therapy v thoracic radiotherapy, 287-288, 290-291
 chemotherapy plus hyperfractionated accelerated radiation therapy, 287-288
 chemotherapy plus radiotherapy, 280, 286-291
 chemotherapy plus surgery, 280-281
 chemotherapy plus surgery and radiotherapy, 284-285
 for rectal cancer, 103-104

Communication
 of bad news, 141-142
 facilitating, 142-143
 goals of, in clinical practice, 140
 information provided in, 141-142
 misconceptions about, 139-140
 physician-patient, 140
 as therapeutic tool, 139

Complications, long-term, of splenectomy for myelofibrosis with myeloid metaplasia, 406-407

Comprehensive Care Team Model, 147, 148

Computed tomography
 high-resolution computed tomography, 259, 262
 low-dose spiral computed tomography, 256-257, 261-262
 in lung cancer screening, 254, 256-257, 259, 261-262
 of malignant pleural mesothelioma, 336-337
 positron emission tomography, 262, 271, 275-276
 staging of mediastinal lymph node metastasis, 270-271, 273

Confocal microscopy, in lung cancer screening, 263

Constipation, management of, 182

Continuous hyperfractionated accelerated radiation therapy, v chemotherapy, in non-small cell lung cancer, 287

Conventional therapy, for myelofibrosis with myeloid metaplasia, 423-424

Corticosteroid
 for anorexia, 201
 as coanalgesic, 188-189

COX-2, 26-27, 183
 in colorectal cancer, 70
 colorectal polyps and, 71-72

COX-2 inhibition
 colorectal polypsis and, 72
 in combined modality therapy, for rectal cancer patient, 108-109
 with cytotoxic chemotherapy, 72-73
 preclinical effects of, 70-71

Cranial irradiation, prophylactic, in central nervous system metastasis, 293-296

Cryoablation, of colorectal cancer hepatic metastases, 87

Cryoneurolysis, 196

Cryotherapy
 definition of, 172
 in thermal ablation, 172-173

Cutaneous malignancies, aberrant DNA methylation in basal cell carcinoma, 480-481

Cutaneous malignancies, aberrant DNA methylation in (*Continued*)
lymphoma, 483-484
melanoma, 481-483
relationship with exposure to ultraviolet radiation, 484
squamous cell carcinoma, 480-481

Cyclooxygenase, 26, 69-70

Cyclooxygenase-2 agents, 183

Cyclooxygenase-2 inhibitors, in non-small cell lung cancer, 323

Cyclophosphamide, doxorubicin, cisplatin chemotherapy regimen, in non-small cell lung cancer, 279

Cytokines, involvement in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 368-370

Cytosine deaminase gene, in prodrug therapy, 91-92

Cytoreductive therapy, for myelofibrosis with myeloid metaplasia, 424

Cytotoxic chemotherapy, in non-small cell lung cancer, 299-312
carboplatin, docetaxel regimen, 301-302
carboplatin, gemcitabine regimen, 300, 302
carboplatin, paclitaxel regimen, 301-302, 306, 308
cisplatin, docetaxel regimen, 301-302
cisplatin, etoposide regimen, 309
cisplatin, gemcitabine, vinorelbine regimen, 303-305
cisplatin, gemcitabine regimen, 300, 301-302
cisplatin, irinotecan regimen, 301
cisplatin, paclitaxel regimen, 302, 309
cisplatin, vindesine regimen, 300, 301, 308
cisplatin, vinorelbine regimen, 301-302, 308
docetaxel, gemcitabine regimen, 303, 308
gemcitabine, vinorelbine regimen, 303, 308-309
gemcitabine monotherapy, 309
ifosfamide, vinorelbine regimen, 303-304
irinotecan monotherapy, 301
mitomycin, vinblastine, cisplatin regimen, 306
paclitaxel, gemcitabine regimen, 303, 309
paclitaxel monotherapy, 308-309
in relation to age, 308-310
vinorelbine monotherapy, 300, 308-309

Decitabine
in epigenetic cancer therapy
activation of apoptotic pathways, 466
for acute myelogenous leukemia, 468-469
antineoplastic activity in animal models, 445-446
background of, 437-438
cellular pharmacology of, 444-445
chemotherapy resensitization, 466-467
for chronic myelogenous leukemia, 469-470
combinations with histone deacetylase inhibitors, 461
dose-schedule optimization of, 447-449, 459-460
drug resistance of, 445
enzyme DNA adduct formation, 466
genomic hypomethylation, 466
hematopoietic toxicity of, 446-447
history of, 438-440, 465
induction of tumor-associated antigens, 466
mechanisms of action, 466
metabolism and molecular mechanism of action, 443-444
for myelodysplastic syndrome, 468
for myeloid neoplasms, 511-512
optimizing silenced gene reexpression, 470
pharmacokinetics of, 447
phase I and II studies, 446
present studies of, 440-441
recent phase I clinical trials, 467
reduced telomerase activity, 466
restoring or enhancing sensitivity to other therapy, 460-461
for solid tumors, 470
for myelofibrosis with myeloid metaplasia, 427

Dehydration, following sedation, 241

Delayed type hypersensitivity testing, 78

Dendritic cell vaccines, genetically modified with tumor antigens, 556
clinical trials
DNA-transfected dendritic cells, 559
RNA-transfected dendritic cells, 557-559
preclinical studies, 557
problems with clinical development, 559-560
rationale, 557

Deoxycholate, 53

Depression, treatment of, 212-214

Desipramine, 187, 189

Dexamethasone, 187, 203

Diagnosis, *see also* Differential diagnosis
of extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 404
of myelofibrosis with myeloid metaplasia, 396-398

Differential diagnosis, of myelofibrosis with myeloid metaplasia, 388-389

Difluoromethylornithine, 28-29
chemoprevention trial of, 26

Dihydropyrimidine dehydrogenase, 114-115, 122

Dissection, mediastinal lymph node, for staging of cancer metastasis, 274-275

Distress
impairment-associated psychological, 220
treatment of, 214-215

dl1520 (ONYX-015), for oncolytic virotherapy, clinical trial results, 542-543

DNA hypomethylating agents, immunomodulatory activity of, 475-477

DNA hypomethylation, in cancer, 523-524

DNA methylation, in cancer
aberrant, *see* Aberrant DNA methylation
tissue-specific, 524
tumor-specific, 525

DNA methylation inhibitors, *see* Azacitidine; Decitabine; DNA hypomethylating agents

DNA mismatch repair system, 25

DNA testing, stool-based, 8-9

DNA-transfected dendritic cells, for cancer immunotherapy, clinical trials, 559

DNAzymes, in multidrug cancer gene therapy, 587

Docetaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302

Docetaxel, cisplatin chemotherapy regimen, in non-small cell lung cancer, 301-302

Docetaxel, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 308

Docetaxel consolidation chemotherapy, in non-small cell lung cancer, 288-289

Docusate sodium, 182

Dose-schedule optimization, of decitabine in epigenetic cancer therapy, 447-449, 459-460

Double-contrast barium enema, 7-8

Douillard regimen, 35

Doxorubicin, cyclophosphamide, cisplatin chemotherapy regimen, in non-small cell lung cancer, 279

Dronabinol, 203
for anorexia, 201

Drug delivery
in cancer pain, 195
direct, 195-196
plexus, 196

Drug resistance
to decitabine in epigenetic cancer therapy, 445
multiple, in cancer, *see* Multidrug resistance cancer

Dukes classification, of colorectal cancer, 96

Dysphagia, malignant, palliation of, 175

Dyspnea
definition of, 204
management of, 205-206
prevalence of, 205

EBUS, *see* Endobronchial ultrasound

Edotecarin, in colorectal cancer, 39

Edrecolomab, 99

Elomithine, 28-29

EGFR, *see* Epidermal growth factor receptor

EGFR-tyrosine kinase inhibitors, in malignant pleural mesothelioma, 342-343

EKB-569, clinical development of, 55, 57

Elderly

- adjuvant chemotherapy in, for colorectal cancer, 100
- first-line colorectal cancer therapy and, 38

Emperipolesis, abnormal, role in cytokine release and pathogenesis of myelofibrosis, 369-370

Endobronchial ultrasound, staging of mediastinal lymph node metastasis, 272, 275

Endo-esophageal ultrasound fine-needle aspiration, staging of mediastinal lymph node metastasis, 272

Endoscopic obstruction, palliation of, 175

Endoscopic retrograde cholangiopancreatography, 176

Endoscopic ultrasound, 174

Enema, phosphate soda, 182

Enteral obstruction, definition and palliation of, 175

Enzyme DNA adduct formation, and decitabine in epigenetic cancer therapy, 466

Enzyme-linked immunospot assay, 78

Epidemiology, bronchioloalveolar carcinoma, 329-330

Epidermal growth factor

- in colorectal cancer growth, 53-54
- in colorectal cancer tumorigenesis, 52-53
- as prognostic factor, in colorectal cancer, 54
- strategies targeting, 54-55

Epidermal growth factor receptor, inhibitor of, in colorectal cancer, 109

Epidermal growth factor receptor inhibition, in non-small cell lung cancer, 316-317

Epigenetic alterations, in lung cancer screening, 264

Epigenetic cancer therapy

- azacitidine in
 - combinations with histone deacetylase inhibitors, 461
 - dose-schedule optimization, 459-460
 - restoring or enhancing sensitivity to other therapy, 460-461
- decitabine in
 - for acute myelogenous leukemia, 468-469
 - antineoplastic activity in animal models, 445-446
 - apoptosis activation by, 466
 - background of, 437-438
 - cellular pharmacology, 444-445
 - chemotherapy resensitization by, 466-467
 - for chronic myelogenous leukemia, 469-470
 - combinations with histone deacetylase inhibitors, 461
 - dose-schedule optimization, 447-449, 459-460
 - drug resistance, 445
 - enzyme DNA adduct formation by, 466
 - genomic hypomethylation by, 466
 - hematopoietic toxicity, 446-447
 - history of, 438-440, 465
 - induction of tumor-associated antigens, 466
 - mechanisms of action, 466
 - metabolism and molecular mechanism of action, 443-444
 - for myelodysplastic syndrome, 468
 - optimizing silenced gene reexpression with, 470
 - pharmacokinetics, 447
 - phase I and II studies, 446
 - present studies of, 440-441
 - recent phase I clinical trials, 467
 - reduced telomerase activity by, 466
 - restoring or enhancing sensitivity to other therapy, 460-461
 - for solid tumors, 470
- immunotherapy, *see* Epigenetic immunotherapy
- for lung cancer, 488-499
 - chromatin remodeling agents, 493-498
 - for myeloid neoplasms
 - cancer testis antigens and, 515-517
 - low-dose azanucleosides, 511-512

Epigenetic cancer therapy (Continued)

- in vivo* markers of demethylation, 512-515

Epigenetic immunotherapy

- for hematopoietic malignancies
 - Hodgkin's lymphoma, 506
 - multiple myeloma, 506-507
 - myeloproliferative disorders, 507-508
 - non-Hodgkin's lymphoma, 504-505
 - primary effusion lymphoma, 505
- for solid tumors
 - cancer testis antigens and, 474
 - DNA hypomethylating agents for, 475-477
 - HLA antigens and, 475-476

Epigenetics, in cancer, *see* Cancer epigenetics

EPO, *see* Erythropoietin

Epothilones, in colorectal cancer, 39

Epstein-Barr virus genomic DNA, as *in vivo* marker of demethylation for myeloid neoplasms, 514-515

Erlotinib, 109

- clinical development of, 55-57
- in non-small cell lung cancer, 318-319

Erythropoietin, for myelofibrosis with myeloid metaplasia, 423-424

Esophageal cancer, palliative radiation therapy in, 160

Esophageal obstruction, palliation in, 175

Etanercept, for myelofibrosis with myeloid metaplasia, 427-428

Ethanol, percutaneous infiltration of, in metastatic colorectal cancer, 88

Etiology, bronchioloalveolar carcinoma, 330

Etoposide

- carboplatin chemotherapy regimen, in non-small cell lung cancer, 289-291
- cisplatin chemotherapy regimen, in non-small cell lung cancer, 309
 - adjuvant chemotherapy, 280-281
 - induction chemotherapy, 285-286

Euthanasia, v sedation, 239-240

External-beam radiation therapy

- palliative, 156-158
 - for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia, 408
 - for respiratory symptoms, 159
- Extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia
 - abdominal radiation for, 408-410
 - diagnosis and imaging of, 404
 - external beam radiotherapy for, 408
 - liver radiation for, 408-410
 - lung radiation for, 410
 - origin of, 404
 - spinal/paraspinal, 410
 - splenic radiation for, 408
 - surgical management of, 405
 - symptomatic, medical palliation of, 405

Facing Our Risk of Cancer Empowered, 216

Familial adenomatous polyposis

- colorectal cancer risk and, 4, 12
- genetics of, 13-15
 - genotype-phenotype correlations in, 15

Farnesyl transferase inhibitors, in non-small cell lung cancer, 319

Fatigue, cancer-related, 200-201

Fecal occult blood testing, 6-7

Fentanyl, 182, 183-184

Fetal hemoglobin expression, as *in vivo* marker of demethylation for myeloid neoplasms, 515

Fibrogenic growth factors, and their receptors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 374-375

Flexible sigmoidoscopy, 7

Fluorescence bronchoscopy, in lung cancer screening, 262

Fluoropyrimidine regimens

- in colorectal cancer, 44
 - survival after, 50
- safety of, 46

Fluorouracil, 113-114
in chemoradiation regimen, for rectal cancer, 103-104
in combination chemotherapy, for colorectal cancer, 96-99

Folate, chemoprevention trial and, 26

FOLFIRI regimen, 49, 100-101
trials of, 36, 40

FOLFOX regimen, 98-100
in colorectal cancer, 47
trials of, 36, 40

Folic acid, in colorectal cancer, 30

Gabapentin, 187, 189

Gamma camera techniques, in lung cancer screening, 263

Ganciclovir, 92

GATA-1 expression, role in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 367-369

Gefitinib, 109
clinical development of, 55-56
in non-small cell lung cancer, 318-319

Gemcitabine, carboplatin chemotherapy regimen, in non-small cell lung cancer, 300, 302

Gemcitabine, cisplatin, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-305

Gemcitabine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300, 301-302
induction chemotherapy, 288

Gemcitabine, docetaxel chemotherapy regimen, in non-small cell lung cancer, 303, 308

Gemcitabine, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 303, 309

Gemcitabine, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303, 308-309

Gemcitabine monotherapy, in non-small cell lung cancer, 309

Gene deletion mutants, use in oncolytic virotherapy
apoptosis inhibition and, 539-540
immune effectors and, 540
interferon pathway inhibition and, 540
p53 pathway inhibition and, 539-540
PKR pathway inhibition and, 540
S-phase induction and, 539

Gene therapy, for cancer, *see* Cancer gene therapy

Gene-directed enzyme prodrug therapy, 91-92

Genetic alterations, in lung cancer screening, 263-264

Genetic testing, for cancer, 215

Genetic translocations, balanced, in myelofibrosis with myeloid metaplasia, 361

Genetics, in lung cancer screening
epigenetic alterations, 264
genetic alterations, 263-264
genetic predisposition, 261
genomic instability, 264
molecular profiling, 264

GFB-111, in malignant pleural mesothelioma, 343

Gleevec, in malignant pleural mesothelioma, 343

GW572016, clinical development of, 55, 57

Gynecologic cancer, palliative radiation therapy in, 161

HART, *see* Hyperfractionated accelerated radiation therapy

Head and neck cancer, palliative radiation therapy in, 161

Heat shock protein, 79, 97

Heating, in thermal ablation, 172-173

Hematologic neoplasms, clinical development of decitabine for acute myelogenous leukemia
combination therapy, 469
monotherapy, 468-469

chronic myelogenous leukemia, 469-470

myelodysplastic syndrome, 468

Hematopathologic findings, in myelofibrosis with myeloid metaplasia, 380-391

Hematopoietic growth factors, and their receptors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 374-375

Hematopoietic neoplasms
epigenetic immunotherapy for
Hodgkin's lymphoma, 506
multiple myeloma, 506-507
myeloproliferative disorders, 507-508
non-Hodgkin's lymphoma, 504-505
primary effusion lymphoma, 505
epigenetic therapy for myeloid neoplasms
cancer testis antigens and, 511-517
low-dose azanucleosides, 511-512
in vivo markers of demethylation, 512-515

Hematopoietic progenitors, and stromal interactions, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 375

Hematopoietic toxicity, to decitabine in epigenetic cancer therapy, 446-447

Hemoglobin expression, fetal, as in vivo marker of demethylation for myeloid neoplasms, 515

Hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 414-420
allogeneic, 414-419
autologous, 419-420

Hepatic artery infusional chemotherapy
for colorectal cancer metastases, 89-90
palliative, 90-91

Hepatic resection, for hepatic metastases, of colorectal cancer, 85-86

Hepatocyte growth factor/scatter factor, in malignant pleural mesothelioma, 344

HER2 inhibition, in non-small cell lung cancer, 319

Hereditary nonpolyposis colon cancer
colorectal cancer risk and, 4, 12
diagnosis of, clinical guidelines for, 16
genetic testing algorithm for, 16
genetics of, 15-17
lifetime risks for, 15

Herpes simplex virus thymidine kinase, in prodrug therapy, 91-92

HGF/SF, *see* Hepatocyte growth factor/scatter factor

High-resolution computed tomography, in lung cancer screening, 259, 262

High-risk population, in lung cancer screening, 260-261

Histology, bronchioloalveolar carcinoma, 328-329

Histone deacetylase inhibitors, combination with DNA methylation inhibitors in epigenetic cancer therapy, 461

Histopathology, and prognosis, of myelofibrosis with myeloid metaplasia, 389-391

HLA antigens, and epigenetic immunotherapy of solid tumors, 475-476

Hodgkin's lymphoma, epigenetic immunotherapy for, 506

Hospice, 135
historical perspective of, 146-147

Hydrocodone, 182, 183-184

Hydromorphone, 182, 183-184

Hyscine, 207

Hyperfractionated accelerated radiation therapy plus induction chemotherapy, in non-small cell lung cancer, 287-288

Hyperfractionated radiation, in non-small cell lung cancer
plus chemotherapy, 287
plus thoracic radiotherapy, 287-288, 290-291

Hypermethylation, of tumor suppressor genes in cancer, 522-523

Hyperplastic polyposis syndrome
clinical diagnostic criteria for, 18-19
colorectal cancer risk and, 12
genetics of, 18-19

Hypertension, portal, *see* Portal hypertension

Hypnosis, 227-228

Hypogastric plexus block, 198

Ibuprofen, 187

Idiopathic myelofibrosis, *see* Myelofibrosis, with myeloid metaplasia

Ifosfamide, mitomycin, and cisplatin chemotherapy regimen, in non-small cell lung cancer, 284

Ifosfamide, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-304

Imaging, of extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 404

Imatinib mesylate, in malignant pleural mesothelioma, 343

Immunotherapy, epigenetic for hematopoietic malignancies

- Hodgkin's lymphoma, 506
- multiple myeloma, 506-507
- myeloproliferative disorders, 507-508
- non-Hodgkin's lymphoma, 504-505
- primary effusion lymphoma, 505

for solid tumors

- cancer testis antigens and, 474
- DNA hypomethylating agents for, 475-477
- HLA antigens and, 475-476

Immunotoxin(s), for cancer, 591-594

Indomethacin, 187

Inflammatory bowel disease, colorectal cancer risk and, 4

Investigational therapy, for myelofibrosis with myeloid metaplasia

- antiangiogenic agents, 424-426
- signal transduction inhibitors, 426-427

Irinotecan

- capecitabine plus, in colorectal cancer, 48, 49
- in combined modality therapy, for rectal cancer, 106-107
- drug pathway of, 115-116
- monotherapy in non-small cell lung cancer, 301
- response to, 124-125
- trials of, 35-38, 40

Irinotecan, cisplatin chemotherapy regimen, in non-small cell lung cancer, 301

Juvenile polyposis syndrome

- clinical diagnostic criteria for, 18
- colorectal cancer risk and, 12
- genetics of, 18

Kaposi's sarcoma, AIDS-associated, palliative radiation therapy in, 161

Ketamine, 244

Ketorolac, 187

Knudson, two hit hypothesis of, 13

K-ras gene, 124

Lactulose, 182

Leflunomide, in malignant pleural mesothelioma, 343

Leucovorin, in combination chemotherapy, for colorectal cancer, 96-99

Levamisole, in combination chemotherapy, for colorectal cancer, 96-99

Levorphanol, 182, 183-184

Lidocaine, topical, 187, 189

Lipiodol, 170

Liver, metastatic disease to, palliative radiation therapy in, 160

Liver radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 408-410

Living Beyond Breast Cancer, 216

LKB1, 17-18

Lonafarnib, in non-small cell lung cancer, 319

Long-term complications, *see* Complications, long-term

Low-dose azanucleosides, in epigenetic therapy of myeloid neoplasms, 511-512

Low-dose spiral computed tomography

- lung cancer screening, 261-262
- non-small cell lung cancer screening, 256-257

Low-fat diet, chemoprevention trial and, 26

Lung adenocarcinoma, uracil tegafur adjuvant chemotherapy, 281

Lung cancer

- epigenetic therapy for, 488-499
- chromatin remodeling agents, 493-498
- non-small cell, 251-252
- adjuvant chemotherapy, 279-283
- central nervous metastasis, 293-296
- chemoprevention, 265
- combination chemotherapy, 284-291, 299-312
- combined modality therapy, 279-291, 293-296

Lung cancer (Continued)

- consolidation chemotherapy, 288-290
- cytotoxic chemotherapy, 299-312
- effects of chemotherapy in relation to age, 308-310
- induction chemotherapy, 284-291
- mediastinal lymph node metastasis, 269-276
- monotherapy v combination chemotherapy, 304-305
- nonplatinum-based doublets in chemotherapy, 302-304
- palliative treatment, 251
- platinum-based doublets in chemotherapy, 300-302
- refractory disease, 306-307
- screening, 251, 253-257, 261
- staging, 251
- targeted therapy, 315-325
- tumor-specific targeted therapy, 251
- vaccine therapy in adjuvant chemotherapy, 282
- palliative radiation therapy in, 159-160
- screening
- autofluorescence bronchoscopy, 254
- biomarkers, 265
- bronchoscopy, 259, 262
- chest roentgenogram, 254-257
- computed tomography, 254, 261-262
- confocal microscopy, 263
- epigenetic alterations, 264
- fluorescence bronchoscopy, 259, 262
- gamma camera techniques, 263
- genetic alterations, 263-264
- genetic predisposition, 261
- genomic instability, 264
- high-resolution computed tomography, 259, 262
- high-risk population, 260-261
- low-dose spiral computed tomography, 256-257, 261-262
- magnetic resonance imaging, 263
- matrix-assisted laser desorption ionization-mass spectroscopy, 265
- molecular imaging, 263
- molecular profiling, 264
- near-infrared Raman spectroscopy, 263
- optical coherence tomography, 263
- positron emission tomography, 262
- proteomic approach, 264-265
- sputum cytology, 254-257, 260-261

Lung radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 410

Lymph node mapping, sentinel, staging of mediastinal lymph node metastasis, 274-275

Lymphadenectomy, staging of mediastinal lymph node metastasis, 274

Lymphoma

- cutaneous, aberrant DNA methylation in, 483-484
- primary effusion, epigenetic immunotherapy for, 505

M.D. Anderson Cancer Center, palliative medicine in, 137

Magnesium citrate, 182

Magnetic resonance imaging

- lung cancer screening, 263
- malignant pleural mesothelioma, 337
- staging of mediastinal lymph node metastasis, 271

MALDI-MS, *see* Matrix-assisted laser desorption ionization-mass spectrometry

Malignant dysphagia, palliation of, 175

Malignant pleural mesothelioma, 251

- anti-EGFR antibody therapy, 341-343
- Avastin, 343-344
- bevacizumab, 343-344
- chemotherapy, 336-341
- computed tomography, 336-337
- EGFR-tyrosine kinase inhibitors, 342-343
- GFR-111, 343
- Gleevec, 343

Malignant pleural mesothelioma, 251 (Continued)
hepatocyte growth factor/scatter factor, 344
imatinib mesylate, 343
leflunomide, 343
magnetic resonance imaging, 337
mammalian target of rapamycin, 344
molecular targeted therapy, 341-345
onconase, 341
pemetrexed, cisplatin regimen, 340-341
pemetrexed treatment, 339-341
platelet-derived growth factor receptor inhibitors, 343
positron emission tomography, 337-338
prognostic factors, 335-336
proteasome/ubiquitin pathway, 344-345
PTK 787, 343
ranpirnase, 341
response to chemotherapy, 336-338
SU101, 343
SU5416, 343
SU11274, 344
thalidomide, 343-344
vascular endothelial growth factor inhibitors, 343-344
Mammalian target of rapamycin, in malignant pleural mesothelioma, 344
Manifest fibrotic stage, of myelofibrosis with myeloid metaplasia, 382-383
Mass spectroscopy, matrix-assisted laser desorption ionization, in lung cancer screening, 265
Massage, 228-229
Matrix metalloproteinase inhibitors, in non-small cell lung cancer, 320
Matrix-assisted laser desorption ionization-mass spectroscopy, in lung cancer screening, 265
Mediastinal lymph node dissection, in metastasis staging, 274-275
Mediastinal lymph node metastasis, in lung cancer
computed tomography, 270-271, 273
dissection, 274-275
endobronchial ultrasound, 272, 275
endo-esophageal ultrasound fine-needle aspiration, 272
lymphadenectomy, 274
magnetic resonance imaging, 271
mediastinoscopy, 272-275
mediastinotomy, 272-274
positron emission tomography, 271, 275-276
sentinel lymph node mapping, 274-275
staging, 269-276
transbronchial needle aspiration, 271-272
video-assisted thoracoscopic surgery, 273-274
Mediastinoscopy, staging of mediastinal lymph node metastasis, 272-275
complications and indications, 273
Mediastinotomy, staging of mediastinal lymph node metastasis, 272-274
complications and indications, 273
Meditation, 228
Megakaryocytes, role of abnormal emperipoleisis in pathogenesis of myelofibrosis, and cytokine release of, 369-370
Megestrol acetate, 203
for anorexia, 201
Melanocytes, atypical capsular, 596-597
Melanoma, cutaneous, aberrant DNA methylation in, 481-483
relationship with exposure to ultraviolet radiation, 484
Meperidine, 182, 183-184
Mesmerism, 227
Mesothelioma, malignant pleural, 251, 335-345
anti-EGFR antibody therapy, 341-343
Avastin, 343-344
bevacizumab, 343-344
chemotherapy, 336-341
computed tomography, 336-337
EGFR-tyrosine kinase inhibitors, 342-343
GFB-111, 343
Gleevec, 343
hepatocyte growth factor/scatter factor, 344
Mesothelioma, malignant pleural, 251, 335-345 (Continued)
imatinib mesylate, 343
leflunomide, 343
magnetic resonance imaging, 337
mammalian target of rapamycin, 344
molecular targeted therapy, 341-345
onconase, 341
pemetrexed, cisplatin regimen, 340-341
pemetrexed treatment, 339-341
platelet-derived growth factor receptor inhibitors, 343
positron emission tomography, 337-338
prognostic factors, 335-336
proteasome/ubiquitin pathway, 344-345
PTK 787, 343
ranpirnase, 341
response to chemotherapy, 336-338
SU101, 343
SU5416, 343
SU11274, 344
thalidomide, 343-344
vascular endothelial growth factor inhibitors, 343-344
Metaplasia, myeloid, with myelofibrosis, see Myelofibrosis with myeloid metaplasia
Metastasis
central nervous system, 293-296
mediastinal lymph node, 269-276
Methadone, 182, 183-184, 188
Methylprednisolone, 187
Mexiletine, 187, 189
Microsatellite instability, 25, 123-124
in colorectal screening, 9
Microscopy, confocal, in lung cancer screening, 263
Microwave ablation, of colorectal cancer hepatic metastases, 87-88
Midazolam, for extraordinary sedation, 243
Milk of magnesia, 182
Mind-body medicine, 227
Mindfulness-based art therapy, 228
Mindfulness-based stress reduction, 228
Mitomycin, ifosfamide, cisplatin chemotherapy regimen, in non-small cell lung cancer, 284
Mitomycin, vinblastine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 306
induction chemotherapy, 287
Mitomycin, vindesine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 280-281
Molecular imaging, in lung cancer screening, 263
Molecular profiling, in lung cancer screening, 264
Molecular targeted therapy
in bronchioloalveolar carcinoma, 331-333
in malignant pleural mesothelioma, 341-345
in non-small cell lung cancer, 315-325
Monoclonal antibody therapy, in colorectal cancer, 99
Monotherapy, in non-small cell lung cancer
gemcitabine, 309
irinotecan, 301
paclitaxel, 308-309
v combination chemotherapy, 304-305
vinorelbine, 300
Morphine, 182, 183-184
Mouse models, pathogenesis of myelofibrosis with myeloid metaplasia, 365-370
MRI, see Magnetic resonance imaging
MTOR, see Mammalian target of rapamycin
Multidrug resistant cancer, gene therapy for
antisense oligonucleotides for, 584-585, 587
characteristics, 583-584
clinical considerations, 587-588
clinical trials, 588
DNAzymes in, 587
"hybrid" transcriptional repressors in, 586-587

Multidrug resistant cancer, gene therapy for (*Continued*)
 ribozymes for, 585, 587
 RNA interference in, 586
 transcriptional decoys in, 586
 triple-forming oligonucleotides for, 585-586

Multiple myeloma, epigenetic immunotherapy for, 506-507

MVP chemotherapy regimen, in non-small cell lung cancer, 280-281

Myelodysplastic syndrome, clinical development program of decitabine for, 468

Myelofibrosis with myeloid metaplasia, 357-358
 abdominal radiation for, 408-410
 androgens for anemia in, 423
 angiogenesis in, 385-386
 antiangiogenic agents for, 424-426
 balanced translocations in, 361
 CD34⁺ progenitor cells in, 386-388
 chromosomal abnormalities in
 chromosome 1, 360
 chromosome 8, 360
 chromosome 9, 360
 chromosome 13, 360-361
 chromosome 20, 361
 clinical consequences of myeloproliferation in, 404
 conventional therapy for, 423-424
 cytogenetic abnormalities and prognosis of, 361
 cytoreductive therapy for, 424
 decitabine for, 427
 diagnosis of, 396-398
 differential diagnosis of, 388-389
 erythropoietin for, 423-424
 etanercept for, 427-428
 extramedullary hematopoiesis in
 diagnosis and imaging of, 404
 external beam radiotherapy for, 408-410
 origin of, 404
 surgical management of, 405
 symptomatic, medical palliation of, 405
 genetic studies on, 361-362
 hematopathologic findings in, 380-391
 hematopoietic stem cell transplantation for, 414-420
 allogeneic, 414-419
 autologous, 419-420
 investigational therapy for, 424-427
 liver radiation for, 408-410
 lung radiation for, 410
 manifest fibrotic stage of, 382-383
 mouse models of, 365-370
 natural history and survival in, 398
 pathogenesis of, 365-370
 abnormal emperipoleisis in, 369-370
 cytokines in, 368-369
 GATA-1 expression in, 367-369
 thrombopoietin overexpression in, 366-367
 pirfenidone for, 427
 profibrotic stage of, 381-382
 prognosis and histopathology of, 389-391
 prognostic factors and staging systems of, 399-401
 proliferation and apoptosis in, 383-385
 signal transduction inhibitors for, 426-427
 splenectomy for, 405-407
 splenic radiation for, 408
 stem cell dysregulation in, 373-377
 fibrogenic growth factors and their receptors in, 374-375
 hematopoietic growth factors and their receptors in, 374-375
 hematopoietic progenitors in, 375
 signaling in, 375-376
 stromal interactions in, 375
 transcription factors in, 375-376
 surgery and radiotherapy for, 403-411
 surgical palliation of portal hypertension in, 408

Myelogenous leukemia
 acute, *see* Acute myelogenous leukemia
 chronic, *see* Chronic myelogenous leukemia

Myeloid metaplasia with myelofibrosis, *see* Myelofibrosis with myeloid metaplasia

Myeloid neoplasms, epigenetic therapy for
 cancer testis antigens and
 expression in neoplasms, 516-517
 as potential in vivo targets, 515-516
 low-dose azanucleosides, 511-512
 in vivo markers of demethylation, 512-515
 Epstein-Barr virus genomic DNA, 514-515
 fetal hemoglobin expression, 515
 p15/INK4B, 514

Myeloproliferation, in myelofibrosis with myeloid metaplasia, clinical consequences of, 404

Myeloproliferative disorders, epigenetic immunotherapy for, 507-508

MYH polyposis syndrome
 colorectal cancer risk and, 12
 genetics of, 17

Myoclonus, treatment of, 206-207

Nabumetone, 187

Nandrolone, 204

National Alliance of Breast Cancer Organizations, 216

National Cancer Institute, 216

Natural history, and survival, in myelofibrosis with myeloid metaplasia, 398

Near-infrared Raman spectroscopy, in lung cancer screening, 263

Needle aspiration, transbronchial, staging of mediastinal lymph node metastasis, 271-272

Neovastat, in non-small cell lung cancer, 320

Neural blockade, 196-197

Neuro-emotional technique, 227

Neurolysis, peripheral, 197-198

Neurostimulation, definition of, 198

Non-Hodgkin's lymphoma, epigenetic immunotherapy for, 504-505

Nonplatinum-based doublets, in non-small cell lung cancer, 302-304
 cisplatin, gemcitabine, vinorelbine regimen, 303-305
 docetaxel, gemcitabine regimen, 303, 308
 gemcitabine, vinorelbine regimen, 303, 308-309
 ifosfamide, vinorelbine regimen, 303-304
 paclitaxel, gemcitabine regimen, 303, 309
 in relation to age, 308-310

Non-small cell lung cancer, 251-252
 adjuvant chemotherapy, 279-283
 central nervous system metastasis, 293-296
 chemoprevention, 265
 combination chemotherapy, 284-291, 299-312
 combined modality therapy, 279-291, 293-296
 consolidation chemotherapy, 288-290
 cytotoxic chemotherapy, 299-312
 effects of chemotherapy in relation to age, 308-310
 induction chemotherapy, 284-291
 mediastinal lymph node metastasis, 269-276
 monotherapy v combination chemotherapy, 304-305
 nonplatinum-based doublets in chemotherapy, 302-304
 palliative chemotherapy in, 150-152
 palliative treatment, 251
 platinum-based doublets in chemotherapy, 300-302
 refractory disease, 306-307
 screening, 251, 253-257, 261
 staging, 251
 targeted therapy, 315-325
 tumor-specific targeted therapy, 251
 vaccine therapy in adjuvant chemotherapy, 282

Nonsteroidal anti-inflammatory drugs
 antitumor effects of, 26-27
 colorectal cancer and, 25-28

Nortriptyline, 187, 189

Nucleic acid vaccine, trials of, 79-80

Nurse case management, in palliative medicine, 136

Octreotide, 187, 190

Ocular metastasis, palliative radiation therapy in, 161

Oligonucleotides

- antisense, *see* Antisense oligonucleotides
- phosphodiester, *see* Phosphodiester oligonucleotides
- phosphorothioate, *see* Phosphorothioate oligonucleotides
- second-generation, *see* Second-generation oligonucleotides
- triple-forming, *see* Triple-forming oligonucleotides

Omega-3 fatty acids, for anorexia, 201

Oncogene inactivation, antisense oligonucleotides for

- Bcl-2 inhibition and, 568-569
- cellular internalization, 564-565
- chemically synthesized, properties of, 564
- clinical utility of phosphodiester oligonucleotides, 563-564
- phosphorothioate oligonucleotides
 - efficacy of, and RNase H, 566
 - general properties, 565
 - nonspecific effects, 565-566
 - pharmacokinetics, 566-569
- second-generation oligonucleotides, pharmacokinetics, 568

Oncolytic virotherapy

- addition of exogenous genes, 543-545
- adenoviral vectors for, 579-580
- clinical trial results of dl1520 (ONYX-015), 542-543
- designing and screening vectors, 545
- mechanisms for achieving tumor targeting or selectivity
 - bioselection approaches, 542
 - inherently selective viruses, 538
 - tumor- or tissue-specific expression of early viral genes, 540-541
 - viral gene deletion mutants, 539-540
 - virus retargeting for tumor-selective uptake, 541-542
 - virus selection and design, 537-538

Onconase, in malignant pleural mesothelioma, 341

ONYX-015, 92

- for oncolytic virotherapy, clinical trial results, 542-543

Optical coherence tomography, in lung cancer screening, 263

Osteosclerosis, and myelofibrosis, in mouse models, pathogenesis of

- cytokines involved in, 368-369
- GATA-1 expression in, 367-368
- thrombopoietin overexpression in, 366-367

Outcomes, of splenectomy for myelofibrosis with myeloid metaplasia, 406-407

Oxaliplatin

- capecitabine plus, in colorectal cancer, 46-47, 49
- in combination chemotherapy, for colorectal cancer, 98-99
- in combined modality therapy, for rectal cancer, 107-108
- drug pathway of, 116-117
- response to, 124-125
- trials of, 35-38, 40

Oxandrolone, 204

- for anorexia, 201

Oxaprozin, 187

Oxycodone, 182, 183-184

p14^{ARF}/mdm2/p53 pathway, in cell cycle progression in cancer, 454-455

p15/INK4B, as *in vivo* marker of demethylation for myeloid neoplasms, 514

p53 gene, 122-123

- in colorectal screening, 9

Paclitaxel

- consolidation chemotherapy, in non-small cell lung cancer, 290
- monotherapy, in non-small cell lung cancer, 308-309
- Paclitaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302, 306, 308
- adjuvant chemotherapy, 281
- induction chemotherapy, 287-289

Paclitaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302, 306, 308 (*Continued*)

Paclitaxel, cisplatin chemotherapy regimen, in non-small cell lung cancer, 302, 309

- induction chemotherapy, 288

Paclitaxel, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 309

Pain, of cancer, *see* Cancer pain

Palliative care

- definition of, 131
- end points in, 167
- mixed management models of, 147
- surgical interventions in, 166

Palliative chemotherapy, 147-149

- alternatives to, 152
- in non-small cell lung cancer, 151
- outcomes of, 150
- in pancreatic cancer, 150
- in prostate cancer, 151-152
- quality of life and, 149
- toxicity of, 149-150

Palliative medicine

- acute inpatient, 135-136
- acute inpatient unit of, 135
- consultation service in, 135
- evidence-based research in, 137
- financial aspects of, 136
- home care service of, 135
- medical oncology and, 134
- nurse case management in, 136
- outpatient clinic service of, 135
- patient service access points in, 136
- physician education in, 137
- physician in, 134-135

Palliative radiation therapy

- external-beam, 156-158
- for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia
 - abdominal radiation, 408-410
 - external-beam radiotherapy, 408
 - liver radiation, 408-410
 - lung radiation, 410
 - splenic radiation, 408
 - fractional schedules in, 157
 - large-field, 158
 - single-fraction, 157

Palliative sedation, 238

Palliative surgery, definition of, 165

Palliative treatment, in non-small cell lung cancer, 251

Pamidronate, 187, 189

Pancreas, metastatic disease to, palliative radiation therapy in, 160

Pancreatic cancer, palliative chemotherapy in, 150-152

Panitumumab, clinical development of, 55, 56

Paravertebral nerve block, 197

Patient selection, for splenectomy, in myelofibrosis with myeloid metaplasia, 407

PDGF, *see* Platelet-derived growth factor

Pemetrexed

- in colorectal cancer, 38-39
- in malignant pleural mesothelioma, 339-341
 - plus cisplatin, 340-341

Peptide vaccine, trials of, 78-79

Percutaneous catheter, 195

Percutaneous ethanol infiltration, in metastatic colorectal cancer, 88

Peripheral neuropathy, 197-198

Peutz-Jegher's syndrome

- colorectal cancer risk and, 12
- diagnostic criteria for, 18
- genetics of, 17-18
- screening guidelines for, 18

Phase I trial, of chemotherapy, 152-154

Phenytoin, 187, 189
 PhoenixCare, 147, 148
 Phosphate soda enema, 182
 Phosphodiester oligonucleotides, for oncogene inactivation, clinical utility, 563-564
 Phosphorothioate oligonucleotides, for oncogene inactivation
 efficacy of, and RNase H, 566
 general properties, 565
 nonspecific effects, 565-566
 pharmacokinetics, 566-569
 Physician-assisted suicide, v sedation, 239-240
 Pirfenidone, for myelofibrosis with myeloid metaplasia, 427
 Piroxicam, chemoprevention trial and, 26
 PKI 166, clinical development of, 55, 57
 Platinum, vindesine chemotherapy regimen, in non-small cell lung cancer, 279-280
 Platinum-based doublets, in non-small cell lung cancer, 300-302
 carboplatin, docetaxel regimen, 301-302
 carboplatin, gemcitabine regimen, 302
 carboplatin, paclitaxel regimen, 301-302, 306, 308
 cisplatin, docetaxel regimen, 301-302
 cisplatin, etoposide regimen, 309
 cisplatin, gemcitabine regimen, 300-302
 cisplatin, irinotecan regimen, 301
 cisplatin, paclitaxel regimen, 302, 309
 cisplatin, vindesine regimen, 300-301, 308
 cisplatin, vinorelbine regimen, 301-302, 308
 in relation to age, 308-310
 Pleural mesothelioma, malignant, 251, 335-345
 anti-EGFR antibody therapy, 341-343
 Avastin, 343-344
 bevacizumab, 343-344
 chemotherapy, 336-341
 computed tomography, 336-337
 EGFR-tyrosine kinase inhibitors, 342-343
 GFB-111, 343
 Gleevec, 343
 hepatocyte growth factor/scatter factor, 344
 imatinib mesylate, 343
 leflunomide, 343
 magnetic resonance imaging, 337
 mammalian target of rapamycin, 344
 molecular targeted therapy, 341-345
 onconase, 341
 pemetrexed, cisplatin regimen, 340-341
 treatment, 339-341
 platelet-derived growth factor inhibitors, 343
 positron emission tomography, 337-338
 factors, 335-336
 proteasome/ubiquitin pathway, 344-345
 PTK 787, 343
 ranpirnase, 341
 response to chemotherapy, 336-338
 SU101, 343
 SU5416, 343
 SU11274, 343
 thalidomide, 343-344
 vascular endothelial growth factor inhibitors, 343-344
 Polyethylene glycol, 182
 Polymorphism, 11307K APC, 19
 colorectal cancer risk and, 12
 Poppy seed oil, iodinated, 170
 Portal hypertension, in myelofibrosis with myeloid metaplasia, surgical palliation of, 408
 Positron emission tomography
 in lung cancer screening, 262
 in malignant pleural mesothelioma, 337-338
 staging of mediastinal lymph node metastasis, 271, 275-276
 Post-operative complications
 of mediastinoscopy, 273
 of mediastinotomy, 273
 Poxviral vaccines, for cancer immunotherapy, 549
 costimulation into, 551-552
 tumor-associated antigens and, 550
 clinical trials, 550-553
 pRB/p16^{INK4}/cyclin D1 pathway, in cell cycle progression in cancer, 452-454
 Prednisone, 187
 Prefibrotic stage, of myelofibrosis with myeloid metaplasia, 381-382
 Prevention of lung cancer, chemoprevention, 265
 Primary effusion lymphoma, epigenetic immunotherapy for, 505
 Principle of double effect, 240
 Prinomastat, in non-small cell lung cancer, 320
 Prognosis, and histopathology, of myelofibrosis with myeloid metaplasia, 389-391
 Prognostic factors
 of bronchioloalveolar carcinoma, 330
 of malignant pleural mesothelioma, 335-336
 and staging systems, of myelofibrosis with myeloid metaplasia, 399-401
 Project Safe-Conduct, 147, 148
 Proliferation, and apoptosis, in myelofibrosis with myeloid metaplasia, 383-385
 Prophylactic cranial irradiation, in central nervous system metastasis, 293-296
 Propofol, for extraordinary sedation, 243
 Prostate cancer
 palliative chemotherapy in, 150-152
 palliative radiation therapy in, 161
 poxviral vaccines for, 553
 Prostate-specific antigen (PSA), and poxviral vaccines
 in cancer immunotherapy, 550
 clinical trials of, 552-553
 Proteasome/ubiquitin pathway, in malignant pleural mesothelioma, 344-345
 Protein kinase c inhibitors, in non-small cell lung cancer, 320
 Protein vaccine, trials of, 78-79
 Proteomic approach, in lung cancer screening, 264-265
 PSA, see Prostate-specific antigen
 Psychoeducational intervention, 215
 Psychosocial oncology, definition of, 212
 PTK 787, in malignant pleural mesothelioma, 343
 Qigong, 226-227
 Quality of life, 145-146
 palliative chemotherapy and, 149
 Radiation
 capecitabine plus, 106
 in rectal cancer, 49-50
 ultraviolet, exposure to, relationship with DNA methylation in cutaneous malignancies, 484
 Radiation therapy, see Radiotherapy
 Radiofrequency ablation, of colorectal cancer hepatic metastases, 86-87
 Radiofrequency neurolysis, 196
 Radiofrequency thermogangliolysis, 197
 Radionuclide, systemic, 158
 Radiosurgery, 159
 Radiotherapy
 for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia
 abdominal radiation, 408-410
 external-beam radiotherapy, 408
 liver radiation, 408-410
 lung radiation, 410
 splenic radiation, 408
 in non-small cell lung cancer
 continuous hyperfractionated accelerated radiation therapy v chemotherapy, 287
 hyperfractionated accelerated radiation therapy plus induction chemotherapy, 287-288
 hyperfractionated radiation therapy plus chemotherapy, 287

Radiotherapy (Continued)
plus adjuvant chemotherapy, 280
plus induction chemotherapy, 286-291
and surgery plus induction chemotherapy, 284-285
v hyperfractionated radiation, 287-288, 290-291
palliative, *see* Palliative radiation therapy
whole-brain, 159

Ranpirnase, in malignant pleural mesothelioma, 341

Rattle, treatment of, 207

Rectal cancer
capecitabine plus radiation in, 49-50
chemoradiation in, 49-50
combined modality therapy in, 103-104
palliative radiation therapy in, 160
pre- v postoperative adjuvant therapy in, 105-106
sphincter preservation in, 104

Refractory non-small cell lung cancer, 306-307

Replication-selective virotherapy, 92

Respiratory symptoms
endobronchial radiation for, 159-160
external-beam radiation therapy for, 159

Retinoids, in non-small cell lung cancer, 320

Ribozymes, for multidrug resistant cancer gene therapy, 585, 587

RNA interference
in cancer, 522
in multidrug resistant cancer gene therapy, 586

RNase H, and mechanism of antisense efficacy for oncogene inactivation, 566

RNA-transfected dendritic cells, for cancer immunotherapy, clinical trials of, 557-559

Rofecoxib, in combination therapy, for colorectal cancer, 73

Royal Marsden Hospital, palliative medicine in, 137

Saltz regimen, 36

Samarium-153, 187, 189

SCH 58500, 91

Sclerosant injection, 175

Scopolamine, 207

Screening
lung cancer, 259-266
biomarkers, 265
bronchoscopy, 259, 262
confocal microscopy, 263
epigenetic alterations, 264
fluorescence bronchoscopy, 259, 262
gamma camera screening, 263
genetic alterations, 263-264
genetic predisposition, 261
genomic instability, 264
high-resolution computed tomography, 259, 262
high-risk population, 260-261
low-dose spiral computed tomography, 261-262
magnetic resonance imaging, 263
matrix-assisted laser desorption ionization-mass spectroscopy, 265
molecular imaging, 263
molecular profiling, 264
near-infrared Raman spectroscopy, 263
optical coherence tomography, 263
positron emission tomography, 262
proteomic approach, 264-265
sputum cytology, 260-261

non-small cell lung cancer, 251, 253-257
auto-fluorescence bronchoscopy, 254
chest roentgenogram, 254-257
computed tomography, 254
low-dose spiral computed tomography, 256-257, 261
sputum cytology, 254-257

Screening recommendations, for colorectal cancer, 5, 6

Sedation
dehydration following, 241

Sedation (Continued)
drugs for, 242-244
extraordinary, 243-244
infrequent, 242-243
for intractable distress in dying patient, 238
palliative, 238
patient monitoring in, 244
patient selection for, 241-242
routine, 242
starvation following, 241
terminal, 237-238

Selenium
chemoprevention trial of, 26
in colorectal cancer, 30

Self-expanding metal stent, 174-175
in esophageal obstruction, 175

Semaxanib, in non-small cell lung cancer, 321

Sentinel lymph node mapping, staging of mediastinal lymph node metastasis, 274-275

Signal transduction inhibitors, for myelofibrosis with myeloid metaplasia, 426-427

Signaling, and transcription factors, in stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 375-376

Simultaneous Care Model, 147, 148

SirSphere, 170

Solid tumors
clinical development of decitabine for, 469
epigenetic immunotherapy for
cancer testis antigens and, 474
DNA hypomethylating agents for, 475-477
HLA antigens and, 475-476

Spinal cord compression, 159

Spinal/paraspinal extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 410

Spirituality, clinical impact of, 233-235

Splenectomy, for myelofibrosis with myeloid metaplasia, 405-407
long-term complications of, 407
outcomes of, 406-407
patient selection for, 407

Splenic radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 408

Splenomegaly, palliative radiation therapy in, 161

Sputum cytology
in lung cancer screening, 260-261
in non-small cell lung cancer screening, 254-257

Squamous cell carcinoma, aberrant DNA methylation in, 480-481
relationship with exposure to ultraviolet radiation, 484

Staging
mediastinal lymph node metastasis, 269-276
computed tomography, 270-271, 273
dissection, 274-275
endobronchial ultrasound, 272, 275
endo-esophageal ultrasound fine-needle aspiration, 272
lymphadenectomy, 272
magnetic resonance imaging, 271
mediastinoscopy, 272-275
mediastinotomy, 272-274
positron emission tomography, 271, 275-276
sentinel lymph node mapping, 274-275
transbronchial needle aspiration, 271-272
video-assisted thoracoscopic surgery, 273-274

non-small cell lung cancer, 251

Staging systems, and prognostic factors, of myelofibrosis with myeloid metaplasia, 399-401

Starvation, following sedation, 241

Stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 373-377
hematopoietic and fibrogenic growth factors and their receptors, 374-375
hematopoietic progenitors and stromal interactions, 375
signaling and transcription factors in, 375-376

Stool-based DNA testing, 8-9
 Stromal interactions, and hematopoietic progenitors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 375
 Strontium 89, 158, 187, 189
 SU101, in malignant pleural mesothelioma, 343
 SU5416, in malignant pleural mesothelioma, 343
 SU6668, in non-small cell lung cancer, 321-322
 SU11274, in malignant pleural mesothelioma, 344
 Suicide gene therapy, in cancer, adenoviral vectors for, 578
 Sulindac/eflornithine, chemoprevention trial of, 26
 Sumatriptan 153, 158
 Superior vena cava syndrome, palliative radiation therapy for, 160
 Support group, 215
 Surgery
 for myelofibrosis with myeloid metaplasia, 403-408
 splenectomy, 405-407
 in non-small cell lung cancer
 plus adjuvant chemotherapy, 279-281
 and radiotherapy plus induction chemotherapy, 284-285
 palliative, definition of, 165
 Surveillance recommendations, for colorectal cancer, 5
 Survival, and natural history, in myelofibrosis with myeloid metaplasia, 398

Targeted therapy, in non-small cell lung cancer, 315-325
 afatinib, 320
 angiogenesis inhibitors, 320-323
 anti-EGFR monoclonal antibody therapy, 317-318
 anti-VEGFR monoclonal antibody therapy, 321
 bevacizumab, 321
 bexarotene, 320
 celecoxib, 323
 cetuximab, 317-318
 cyclooxygenase-2 inhibitors, 323
 EGFR inhibition, 316-317
 erlotinib, 318-319
 farnesyl transferase inhibitors, 319
 gefitinib, 318-319
 HER2 inhibition, 319
 lonafarnib, 319
 matrix metalloproteinase inhibitors, 320
 neovastat, 320
 primostat, 320
 protein kinase c inhibitors, 320
 retinoids, 320
 semaxanib, 321
 SU6668, 321-322
 tipifarnib, 319
 trastuzumab, 319
 ZD6126, 322
 ZD6474, 322

TBNA, see Transbronchial needle aspiration
 Telomerase activity, reduced by decitabine in epigenetic cancer therapy, 466
 Terminal sedation, 237-238
 Tezacetabine, in colorectal cancer, 39-40
 Thalidomide, 204
 in colorectal cancer, 65, 66
 in malignant pleural mesothelioma, 343-344
 Thermal ablation, definition of, 172
 Thiopental, for extraordinary sedation, 243
 Thoracoscopic surgery, video-assisted, staging of mediastinal lymph metastasis, 273-274
 Thrombopoietin overexpression, role in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 366-367
 Thymidine phosphorylase, 122
 Thymidine synthase, 113-114
 Thymidylate synthase, 120-122

Tipifarnib, in non-small cell lung cancer, 319
 TNM classification, of colorectal cancer, 96
 Tomography, optical coherence, see Optical coherence tomography
 Total sedation, 238
 Toxin conjugates, see Immunotoxin(s)
 TPO, see Thrombopoietin
 Traditional Chinese medicine, 225-226
 Tramadol, 183
 Transbronchial needle aspiration, staging of mediastinal lymph node metastasis in lung cancer, 271-272
 Transcription factors, and signaling, in stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 375-376
 Transcutaneous electrical nerve stimulation, 198
 Trastuzumab, in non-small cell lung cancer, 319
 Tricyclic antidepressant, as coanalgesic, 188-189
 Trigeminal balloon compression, 197
 Triple-forming oligonucleotides, for multidrug resistant cancer gene therapy, 585-586

Tumor suppressor genes
 hypermethylation in cancer, 522-523
 transfer of, 91

Tumor-associated antigens
 and epigenetic immunotherapy for solid tumors
 cancer testis antigens, 474
 HLA antigens, 475-476
 genetically modified dendritic cell vaccines with, 556
 clinical trials, 557-559
 preclinical studies, 557
 problems with clinical development, 559-560
 rationale, 557
 induction by decitabine for epigenetic cancer therapy, 466
 and poxviral vaccines, 550
 clinical trials, 550-553

Tumor-specific targeted therapy, in non-small cell lung cancer, 251

Two hit hypothesis, 13

Tyrosine kinase phosphorylation, 53

UFT, see Uracil/tegafur
 Ultrasound, endobronchial, staging of mediastinal lymph node metastasis, 272
 Ultraviolet radiation, exposure to, relationship with DNA methylation in cutaneous malignancies, 484

Uracil/tegafur adjuvant chemotherapy, in lung adenocarcinoma, 281
 Ursodeoxycholic acid, 29
 chemoprevention trial of, 26

Vaccine
 dendritic cell, see Dendritic cell vaccines
 goals of, 77-78
 poxviral, see Poxviral vaccines
 types of, 78
 varying formats of, 77

Vaccine therapy, in non-small cell lung cancer, 282

Vaccinia, 80

Vascular endothelial growth factor
 anti-, inhibitors of, 62-63
 biology of, in tumor angiogenesis, 62

Vascular endothelial growth factor inhibitors, in malignant pleural mesothelioma, 343-344

Vascular obstruction, 170-171

Vascular therapy, 169-170

Vatalanib, in colorectal cancer, 65, 66

VATS, see Video-assisted thoracoscopic surgery

Vectors, adenoviral, see Adenoviral vectors

VEGF, see Vascular endothelial growth factor

Video-assisted thoracoscopic surgery, staging of mediastinal lymph metastasis, 273-274

Vinblastine, cisplatin induction chemotherapy regimen, in non-small cell lung cancer, 286

Vinblastine, mitomycin, cisplatin chemotherapy regimen, in non-small cell lung cancer, 306
induction chemotherapy, 287

Vindesine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300-301, 308
induction chemotherapy, 284-285

Vindesine, mitomycin, cisplatin adjuvant chemotherapy regimen, in non-small cell lung cancer, 280-281

Vindesine, platinum chemotherapy regimen, in non-small cell lung cancer, 279-280

Vinorelbine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300-302, 308
adjuvant chemotherapy, 281
induction chemotherapy, 288

Vinorelbine, gemcitabine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 303-305

Vinorelbine, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 308-309

Vinorelbine, ifosfamide chemotherapy regimen, in non-small cell lung cancer, 303-304

Vinorelbine monotherapy, in non-small cell lung cancer, 300, 308-309

Virally encoded vaccine, trial of, 80-81

Virotherapy, for cancer, *see* Oncolytic virotherapy

Virtual colonoscopy, 8

Viruses, for cancer therapy, *see* Oncolytic virotherapy

Vitamins, chemoprevention trial and, 26

Wellness Community, 216

Whole cell vaccine, 77
trials of, 78

Wnt signaling pathway, 14

World Health Organization, cancer management model of, 135

XELIRI regimen, in colorectal cancer, 48-49

Xeloda adjuvant chemotherapy trial, 45

XELOX regimen, in colorectal cancer, 46-48

Yoga, 228

Young Survival Coalition, 216

ZD6126, in non-small cell lung cancer, 322

ZD6474, in non-small cell lung cancer, 322

Zolendronate, 187, 189